INCHEON, Korea--(BUSINESS WIRE)-- #Biosimilar--Samsung Bioepis Co., Ltd. today announced the launch of OBODENCEâ"¢ (60 mg pre-filled syringe) and XBRYKâ"¢ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. "We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability ch ...

INCHEON, Korea--(BUSINESS WIRE)-- #BYOOVIZ--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis' two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen b. ...

Core Insights - Samsung Bioepis and Phrontline Biopharma have entered into a global collaboration agreement to develop, manufacture, and commercialize two Antibody-Drug Conjugate (ADC) assets [1] - The ADC assets include TJ108, which is a bispecific and dual-payload ADC, and another unnamed asset [1] - Samsung Bioepis will receive an exclusive license from Phrontline for one of the ADC assets [1]